1. Heart transplantation and anti‐HLA antibodY: myocardial dysfunction and prognosis ‐ HeartLAy study
- Author
-
Carlotta Sciaccaluga, Benedetta Maria Natali, Francesca Maria Righini, Carlotta Sorini Dini, Federico Landra, Giulia Elena Mandoli, Nicolò Sisti, Daniele Menci, Antonio D'Errico, Flavio D'Ascenzi, Marta Focardi, Sonia Bernazzali, Massimo Maccherini, Serafina Valente, and Matteo Cameli
- Subjects
Heart transplantation ,Anti‐HLA antibody ,Antibody‐mediated rejection ,Prognosis ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Aims The presence of anti‐human leucocyte antigen (HLA) antibodies has been implicated in a higher incidence of complications as well as mortality rate in heart transplantation. The aim of the study was to identify through non‐invasive parameters early signs of myocardial dysfunction in the presence of anti‐HLA antibodies but without evidence of antibody‐mediated rejection (AMR) and its possible prognostic impact. Methods and results A total of 113 heart‐transplanted patients without acute cellular rejection (ACR) and AMR or cardiac allograft vasculopathy (CAV) were prospectively enrolled and divided into two groups [‘HLA+’ (50 patients) and ‘HLA−’ (63 patients)], based on the presence of anti‐HLA antibodies. Each patient was followed for 2 years after the enrolment, recording episodes of AMR, ACR, CAV, and mortality. Clinical characteristics were similar between the two groups. Among laboratory data, N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity cardiac troponin values were significantly higher in the presence of anti‐HLA antibodies (P
- Published
- 2023
- Full Text
- View/download PDF